{"mainPropery":{"diseaseId":522,"diseaseName":"Acute lymphoblastic leukemia","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/522/acute-lymphoblastic-leukemia","synonyms":["ALL","Acute lymphocytic leukemia"],"synonyms-with-source":[{"name":"ALL"},{"name":"Acute lymphocytic leukemia"}],"identifiers":[{"identifierType":"OMIM","identifierId":"613065"},{"identifierType":"ORPHANET","identifierId":"513"},{"identifierType":"NCI Thesaurus","identifierId":"C3167"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":120,"resourceName":"American Cancer Society","abbreviation":"","address1":"250 Williams Street NW","address2":"","address3":"","address4":"","address5":"","city":"Atlanta","state":"GA","zip":"30329","country":"United States","phone":"","tty":"","tollFree":"1-800-227-2345","fax":"","email":"","url":"https://www.cancer.org","freeText":""},{"resourceID":570,"resourceName":"Leukemia and Lymphoma Society","abbreviation":"","address1":"3 International Drive, Suite 200","address2":"","address3":"","address4":"","address5":"","city":"Rye Brook","state":"NY","zip":"10573","country":"United States","phone":"1-(888) 557-7177 (general)","tty":"","tollFree":"1-(800) 955-4572 (patients and families)","fax":"","email":"https://www.lls.org/content/contact-us","url":"https://www.lls.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/613065' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Acute+lymphoblastic+leukemia%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Acute lymphoblastic leukemia. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1003,"resourceId":120,"resourceName":"American Cancer Society","descriptionText":"The <a href='https://www.cancer.org/cancer/acute-lymphocytic-leukemia/about/what-is-all.html' target='_blank'>American Cancer Society</a>&nbsp;provides more information on Acute lymphoblastic leukemia.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0023449' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='https://medlineplus.gov/ency/article/000541.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='https://emedicine.medscape.com/article/207631-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1532,"resourceId":2163,"resourceName":"Social Security Administration","descriptionText":"The <a href='https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022085' target='_blank'>Social Security Administration</a> has included this condition in their Compassionate Allowances Initiative. This initiative speeds up the processing of disability claims for applicants with certain medical conditions that cause severe disability. More information about <a href=\"http://www.ssa.gov/compassionateallowances/index.htm\" target=\"_blank\">Compassionate Allowances</a> and <a href=\"https://www.ssa.gov/benefits/disability/\" target=\"_blank\">applying for Social Security disability</a> is available online.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=513' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The National Cancer Institute provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n<a href='https://www.cancer.gov/types/leukemia/patient/adult-all-treatment-pdq' target='_blank'>Adult acute lymphoblastic leukemia</a><br /><a href='https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq' target='_blank'>Childhood acute lymphoblastic leukemia</a><br />","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1763,"resourceId":570,"resourceName":"Leukemia and Lymphoma Society","descriptionText":"The <a href='https://www.lls.org/leukemia/acute-lymphoblastic-leukemia' target='_blank'>Leukemia and Lymphoma Society</a> has an information page on Acute lymphoblastic leukemia. Click on the link to view this information page.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1764,"resourceId":2924,"resourceName":"Mayo Clinic","descriptionText":"The <a href='https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/basics/definition/con-20042915' target='_blank'>Mayo Clinic</a> Web site provides further information on Acute lymphoblastic leukemia.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1949,"resourceId":2776,"resourceName":"KidsHealth from Nemours","descriptionText":"<a href='http://kidshealth.org/en/parents/all.html' target='_blank'>KidsHealth from Nemours</a> has an information page on Acute lymphoblastic leukemia. Click on the link to access this resource.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:613065' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":12339,"questionText":"What is acute lymphoblastic leukemia?","answerText":"<strong>Acute lymphoblastic leukemia</strong> (ALL) is a type of cancer&nbsp;in which the bone marrow makes too many <a href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45765\" target=\"_blank\">lymphocytes</a> (a type of white blood cell).[14010] It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males).[14009] Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin.[14010][14011]<br />\r\n<br />\r\nALL is typically caused by random, non-inherited changes in the DNA of immature lymphocytes called lymphoblasts.[14009][14018] However, some people may inherit a genetic susceptibility to developing ALL.[14018] The risk to develop ALL may also be increased by past treatment for cancer, and by having certain genetic conditions or syndromes.&nbsp;Having one or more risk factors does not mean that a person definitely will develop ALL.[14010]<br />\r\n<br />\r\nTreatment of ALL depends on the person's age, how advanced the cancer is, and whether certain genetic changes are found in cancer cells. Treatment options may involve&nbsp;<a href=\"https://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000301626&amp;version=patient&amp;language=English&amp;dictionary=Cancer.gov\" target=\"_blank\">systemic</a> and/or&nbsp;<a href=\"https://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000046681&amp;version=patient&amp;language=English&amp;dictionary=Cancer.gov\" target=\"_blank\">intrathecal</a> chemotherapy,&nbsp;<a href=\"https://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000044971&amp;version=patient&amp;language=English&amp;dictionary=Cancer.gov\" target=\"_blank\">radiation therapy</a>,&nbsp;<a href=\"https://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000270742&amp;version=patient&amp;language=English&amp;dictionary=Cancer.gov\" target=\"_blank\">targeted therapy</a>, and/or a <a href=\"https://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000046695&amp;version=patient&amp;language=English&amp;dictionary=Cancer.gov\" target=\"_blank\">stem cell transplant</a>.[14010][14011]&nbsp;<a href=\"https://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000045617&amp;version=patient&amp;language=English&amp;dictionary=Cancer.gov\" target=\"_blank\">Biologic therapy</a> and <a href=\"https://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000771301&amp;version=patient&amp;language=English&amp;dictionary=Cancer.gov\" target=\"_blank\">chimeric antigen receptor (CAR) T-cell therapy</a> are currently being studied as treatment options and may be used when other therapies are not working.[14010][14011]<br />\r\n<br />\r\nThe chance of recovery also depends on many factors.[14010][14011] With treatment, about 98% of children with ALL go into <a href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45867\" target=\"_blank\">remission</a>, and 85% of those with first-time ALL are expected have no long-term complications.[14013] The chance of recovery for adults is not as high, as 20-40% of adults are cured with current treatments.[14012]<br />","dateModified":"2017-10-31T10:10:00"},"basicQuestions":[],"references":[],"relatedDiseases":[{"relatedDiseaseId":9240,"relatedDiseaseName":"Childhood acute lymphoblastic leukemia","relation":"Child","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":86,"phenoTypeName":"Acute lymphoblastic leukemia","percentRanges":"-"},{"phenoTypeId":8168,"phenoTypeName":"Polygenic inheritance","percentRanges":"-"},{"phenoTypeId":8123,"phenoTypeName":"Somatic mutation","percentRanges":"-"}],"medicalProducts":[{"productId":234,"genericName":"Nelarabine","tradeName":"Arranon®","tradeLink":"http://us.gsk.com/products/assets/us_arranon.pdf","manufacturer":"","sponsor":"GlaxoSmithKline","indication":"Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Arranon","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607077.html"},{"productId":692,"genericName":"Inotuzumab ozogamicin","tradeName":"Besponsa","tradeLink":"https://www.besponsa.com/","manufacturer":"","sponsor":"Pfizer, Inc.","indication":"Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/besponsa","medlinePlusLink":""},{"productId":614,"genericName":"Blinatumomab","tradeName":"Blincyto","tradeLink":"http://www.blincytorems.com/","manufacturer":"","sponsor":"Amgen, Inc.","indication":"March 2018 approval for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. Previously approved in December 2014 for treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/blincyto","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a614061.html"},{"productId":208,"genericName":"Clofarabine","tradeName":"Clolar®","tradeLink":"http://www.clolar.com/","manufacturer":"","sponsor":"Genzyme Corporation","indication":"Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Clolar","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a692033.html"},{"productId":400,"genericName":"Buffered intrathecal electrolyte/dextrose injection","tradeName":"Elliotts B Solution","tradeLink":"http://www.elliottsbsolution.com/","manufacturer":"","sponsor":"QOL Medical, LLC","indication":"For the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/elliotts%20b%20solution","medlinePlusLink":""},{"productId":543,"genericName":"Erwinia L-Asparaginase","tradeName":"Erwinase","tradeLink":"http://www.erwinaze.com/hcp/index.html","manufacturer":"","sponsor":"EUSA Pharma, Inc.","indication":"Treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. Coli-derived asparaginase.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=ERWINASE","medlinePlusLink":"http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=56609"},{"productId":516,"genericName":"Imatinib mesylate","tradeName":"Gleevec®","tradeLink":"http://www.gleevec.com/index.jsp?usertrack.filter_applied=true&NovaId=1178761786655757289","manufacturer":"","sponsor":"","indication":"Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Gleevec","medlinePlusLink":""},{"productId":563,"genericName":"Ponatinib","tradeName":"Iclusig","tradeLink":"http://www.ariad.com/wt/page/ICLUSIG","manufacturer":"ARIAD Pharmaceuticals Inc.","sponsor":"ARIAD Pharmaceuticals Inc.","indication":"Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.  ","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name= Iclusig","medlinePlusLink":""},{"productId":550,"genericName":"Vincristine sulfate liposome injection","tradeName":"Marqibo","tradeLink":"http://www.sppirx.com/310-spectrum-products-commercial.html#top","manufacturer":"","sponsor":"Talon Therapeutics, Inc.","indication":"Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.  ","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=marqibo","medlinePlusLink":""},{"productId":166,"genericName":"Pegaspargase","tradeName":"Oncaspar®","tradeLink":"http://www.enzon.com/index.php?id=38","manufacturer":"","sponsor":"Enzon, Inc.","indication":"Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Oncaspar","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a695031.html"},{"productId":599,"genericName":"mercaptopurine oral solution","tradeName":"Purixan","tradeLink":"https://www.optumrx.com/vgnlive/HCP/Assets/RxNews/Drug%20Approvals_2014-0429_Purixan.pdf","manufacturer":"","sponsor":"Nova Laboratories Limited","indication":"Treatment of patients with acute lymphoblastic leukemia as part of a combination regimen.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=PURIXAN","medlinePlusLink":""},{"productId":76,"genericName":"Dasatinib","tradeName":"Sprycel","tradeLink":"https://www.sprycel.com/","manufacturer":"","sponsor":"Bristol-Myers Squibb Company","indication":"December 2018, dasatinib (Sprycel) was approved for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase and newly diagnosed Ph+ ALL in combination with chemotherapy. Previously in June 2013, it was approved for treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/863127-77-9","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a607063.html"},{"productId":676,"genericName":"Methotrexate oral solution","tradeName":"Xatmep","tradeLink":"http://silvergatepharma.com/index.php/2017/04/26/xatmep/","manufacturer":"","sponsor":"Silvergate Pharmaceuticals, Inc.","indication":"April 2017, methotrexate oral solution (Xatmep) was approved for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/xatmep","medlinePlusLink":""}],"EncodedName":"Acute_lymphoblastic_leukemia"}